Choose a language and wait for the translated text.
Shots:
Merck has discontinued the P-III (BELLWAVE-011) study of nemtabrutinib (MK-1026) after an external Data Monitoring Committee review suggested that its benefits may not outweigh the risks in the study
Following a review of the data in its totality, Merck has also discontinued the broader BELLWAVE program, including the P-III (BELLWAVE-008 & BELLWAVE-010) studies in CLL & SLL
Nemtabrutinib is an investigational, oral, non-covalent BTK inhibitor that suppresses oncogenic B-cell receptor signaling; data analyses are ongoing & results will be shared with the scientific community
Ref: Merck | Image: Merck | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Merck Discontinues the Clinical Development Program of Nemtabrutinib Following P-III (BELLWAVE-011) Data Review appeared first on PharmaShots.
Merck Discontinues the Clinical Development Program of Nemtabrutinib Following P-III (BELLWAVE-011) Data Review | PharmaVoice